Introduction: Addiction is increasingly defined as a "brain disease" caused by changes to neurochemistry. While nicotine addiction has historically been excluded in the brain disease model of addiction (BDMA), it is beginning to be labeled a chronic brain disease. We investigated whether Australian smokers endorse brain-based explanations of smoking, and whether these beliefs are associated with quitting self-efficacy or treatment intentions. Method: Cross-sectional study of Australian smokers (N = 1538) who completed a survey measuring their agreement with statements on the brain's role in smoking. Logistic regressions tested associations between these items and socio-demographic variables, quitting self-efficacy and intention to use cessation medications. Results: The majority (57.9%) agreed that smoking changed brain chemistry and 34.4% agreed that smoking was a brain disease. Younger participants and those with more education were more likely to endorse brain-based understandings of smoking. Participants who agreed smoking changed brain chemistry were more likely to report an intention to use cessation medicines (OR 1.5, 95% CI = 1.0-2.2) as were those who agreed that smoking was a brain disease (OR 1.5, 95% CI = 1.1-2.1). Self-efficacy did not differ between those who agreed and disagreed that smoking changed brain chemistry. However, those who agreed that smoking was a brain disease had higher self-efficacy than those who disagreed (OR 1.7, 95% CI = 1.3-2.3). Conclusion: A neurobiological view of smoking does not dominate public understandings of smoking in Australia. Endorsement of neurobiological explanations of smoking were associated with increased intention to use cessation aids, but were not associated with reduced self-efficacy.
Introduction
Drug addiction is increasingly portrayed as a biological phenomenon in which the brain plays the central role. The National Institute of Drug Abuse (NIDA) have long argued that addiction is a "chronic and relapsing brain disease." 1 In 2016, the US Surgeon general released a report claiming that addiction is a brain disease, and treating it as such would reduce the stigma and blame associated with addiction, overcoming many of the barriers to addiction treatment. 2 Similarly the American Society for Addiction Medicine have defined addiction as a "primary, chronic disease of brain reward, motivation, memory and related circuitry." 3 While nicotine has historically been treated differently to other psychoactive drugs, 4 the "brain disease model of addiction" (BDMA) also encompasses nicotine addiction because, like other drugs, nicotine produces long-term changes to neurochemical pathways in the brain. [5] [6] [7] Hence, smoking is increasingly medicalized by being labeled a "chronic brain disorder" 8 and a "chronic disease." [9] [10] [11] A recent report on e-cigarettes and young people by the US Surgeon General has emphasized the potentially damaging effects of nicotine on the adolescent brain 12 and an associated video warns the public of the dangers of "brain risks" to young people from use of e-cigarettes. 13 Smokers are exposed to biomedical explanations of tobacco dependence via the media, where the neurobiological aspects of smoking are reported in articles with titles such as "Smokers who quit may have brains hard-wired for success" 14 and "Quitting is a brain game." 15 Some clinicians have recommended discussing neurobiological aspects of nicotine addiction with smokers in clinical consultations to help them understand why quitting is difficult and to reduce self-blame. 16 Also, novel treatments for smoking cessation based on neuroscience, such as transcranial magnetic stimulation and various new pharmacotherapies, are being investigated. 17, 18 Proponents of the BDMA believe it will reduce the stigma of drug dependence and lead to the development of more efficacious treatments. [19] [20] [21] Those critical of biomedical models have expressed concern that the belief that addiction is "hard-wired" in the brain may lead to fatalism and a diminished sense of self-efficacy. [22] [23] [24] Neuroscience based explanations could contribute to what Dweck has labeled a "fixed mindset" where individuals believe that nature determines their behavior, rather than a "growth" mindset that encourages attempts to change problematic behaviors. 25 Alternatively, understanding addiction as a neurobiological disorder may increase positive perceptions of targeted cessation pharmacotherapies. Knowing that medications are available, and understanding how they work, could make quitting smoking seem easier and encourage more quit attempts. Research from the genetics field has looked at the impact of genetic understandings of tobacco addiction on smokers' sense of control and treatment preferences. [26] [27] [28] Mixed findings and variations in study design limit the conclusions that can be drawn from these studies. Moreover, it remains to be seen if people respond to genetic and neuroscience information in similar ways, given important differences between the two. 29 This paper examines the extent to which Australian smokers endorse neurobiological explanations of smoking, and whether endorsement of neuroscientific explanations of smoking are associated with quitting self-efficacy or preferences for using particular smoking cessation methods.
Method

Design and Sampling
An online survey was completed by 1538 Australian smokers. All participants were recruited from a commercial online research panel in 2015. Panel members were recruited from online and offline sources. Survey completers received points for participation that could be converted into gift vouchers. The invitation strategy was adjusted daily with quotas to obtain a sample representative of the demographic profile of the population of Australian smokers in terms of age and gender. 30 In order to be eligible, participants had to be 18 years old or older, an Australian citizen or resident, to smoke daily, and to have smoked more than 100 cigarettes in their lifetime. The Human Research Ethics Committee of the University of Queensland granted ethics approval for this study (Approval number: 2009001022).
Of the 6520 invited participants who clicked on the link to the survey, 4273 did not smoke daily, 49 had not smoked at least 100 cigarettes and 16 exited the survey before completing the eligibility questions and were excluded. Of those who met the eligibility criteria (N = 2182), 625 dropped out before completing the survey. Seven identified as duplicate cases caused by a computer error were removed from the dataset. Despite reporting daily smoking on the screening questions, 12 participants stated that they smoked zero cigarettes per day on a subsequent question and were excluded from the dataset. For further details of the recruitment process see Supplementary File 1.
Measures
The survey was informed by a literature review and the results of a qualitative study that has been published elsewhere. 31 Given the paucity of research in this area, the survey design was also informed by research in related areas, such as studies of the attitudes of persons experiencing other drug addictions towards the role of the brain in their addictions. [32] [33] [34] Socio-demographic variables are included in Table 1 . Level of nicotine dependence was measured using the Heaviness of Smoking Index (HSI). 35 Desire to quit was assessed by the item "How much do you want to give up smoking?" with response options of: not at all, a little bit, quite a bit, or very much. Those who responded "not at all" were classified as having no to desire to quit, and compared to all others who expressed some level of desire to quit. Quitting self-efficacy was measured using a single item: For the purposes of analysis, responses were dichotomized so that those who responded "not at all" or "slightly sure" were labeled as having low self-efficacy, and the remaining responses were combined to represent "moderate/high" self-efficacy. Participants were provided with a list of smoking cessation strategies and asked to check all that they had previously used. Those who reported having used nicotine replacement therapy (NRT) or prescription medicines (Champix or Zyban) were coded as having used a cessation medication. Intention to use pharmacotherapy in future quit attempts was assessed with the question "If you decided to make a quit attempt, how likely is it that would use the following method." Response options were: "definitely wouldn't use, probably wouldn't use, probably would use, definitely would use, and don't know." Those who selected "probably would use" or "definitely would use" for NRT or prescription medicines were categorized as intending to use medications. All other responses were classed as not intending to use medication.
Four items were developed to assess strength of endorsement of beliefs about the role of neurobiology in smoking. Participants were asked to rate the extent to which they agreed with the following statements on a four-point scale (strongly disagree, disagree, agree, strongly agree) with the option of a "don't know" response: 
Data Analysis
From the four brain beliefs items, two key items measuring the strength of endorsement of brain-based explanations of smoking were selected for further analysis: (1)"Smoking changes the chemistry of the brain"; and (2) "Smoking is a brain disease." These two items were chosen for further investigation because they represented two ways that the role of the brain in smoking has been portrayed.
The first item selected for further analysis, that "Smoking changes the chemistry of the brain" represents the scientific view that smoking influences neurobiological mechanisms that then make it difficult to quit. The second item chosen, "Smoking is a brain disease" represents the controversial NIDA labeling of addiction as a chronic "brain disease." Empirically, the brain disease and brain chemistry items elicited different response patterns amongst participants, while there was significant covariance between other items (for example between "Smoking is a brain disease" and "Smoking is a brain disorder"), which contributed to the decision to retain only these two items for further analysis.
For each of these items, the five point Likert scale was converted into a dichotomous variable comprised of disagree (disagree combined with strongly disagree = 0) and agree (agree combined with strongly agree = 1). We conducted chi-squared and t-tests to determine differences between those who selected "don't know" compared to those who expressed an opinion about brain-based explanations of smoking (Table 1 ). Because our primary research question was whether opinions on brain-based explanations of smoking are related to outcome variables, we excluded from the primary analysis those who selected "don't know" responses on these items.
For each of these two key brain-related items, contingency tables and the Pearson's chi-squared statistic were used to examine which categorical variables were associated with scores on these two items. Age and level of nicotine addiction (HSI) were analyzed as continuous variables using t-tests. Categorical independent variables were gender (male = 0, female = 1), education (did not complete Bachelor degree = 0, completed Bachelor degree = 1), intention to use cessation medication (no intention = 0, intention = 1), and self-efficacy (low = 0, moderate or high = 1).
A binary logistic regression was conducted to explore the relationship between endorsement of each of the two key neurobiological explanations of smoking and intention to use medication in a quit attempt. Intention to use medication was entered as the outcome variable (0 = no intention, 1 = intend to use). SPSS v22 was used for data analysis. All variables were entered into the model simultaneously, with categorical variables dummy coded. Demographic variables and smoking characteristics were gender (male = 0, female = 1), age, level of education (did not complete Bachelor degree = 0, completed Bachelor degree = 1), HSI score, self-efficacy (low = 0, moderate or high = 1), desire to quit (0 = no desire, 1 = some desire) and past use of cessation medications (0 = no, 1 = yes). The included brain-based items were "Smoking is a brain disease" (0 = disagree, 1 = agree) and "Smoking changes the chemistry of the brain" (0 = disagree, 1 = agree).
Another binary logistic regression investigated the relationship between endorsement of neurobiological explanations of smoking and self-efficacy. The outcome variable was a dichotomized version of self-efficacy (0 = low, 1 = moderate or high). Predictor variables were the same smoking characteristics and brain-related items used in the logistic regression described above.
Results
Participant Demographics
Participant demographics are presented in Table 1 . Of the entire sample, participant age ranged from 18-88 years old with a mean of 43 years (SD 16.1). The proportion of the sample born in Australia aligned closely with national population data (72.8% born in Australia). 40 In relation to education, 26.4% had no post-secondary qualification, 32.2% had completed some post-secondary education at less than bachelor degree level, and 31.3% had completed a bachelor degree or higher. The mean number of cigarettes smoked per day was 15 (SD 9.6). Based on previous studies, where the HSI has been categorized as low dependence for scores 0 or 1, moderate dependence for scores 2-4, and high dependence for scores 5-6, 36,41 74.2% of participants reported moderate or high nicotine dependence. Only 7.9% of participants expressed no interest in quitting, with 38% stating that they wanted to give up "a little bit" and 54.2% wanting to quit "quite a bit" or "very much." Almost half (47%) reported low levels of quitting self-efficacy, and 49.6% had used cessation medication for a past quit attempt (either NRT or prescription medication). Approximately two-thirds (67.2%) of participants said that they would use cessation medications if they were to make a quit attempt. Table 1 shows differences between those who were excluded from the analysis because they responded "don't know" to either of the two brain-related items, and those who provided an opinion for both. Those who gave a "don't know" response were older and had lower levels of education. Figure 1 shows the percentage of the entire sample (N = 1538) who agreed or disagreed with the items about the role of the brain in smoking. The majority (57.9%) agreed or strongly agreed that smoking changes brain chemistry. The findings were similar for the statement that smoking damages the brain (54.6% agree or strongly agree). Fewer participants agreed that smoking was a brain disease (34.4% agree or strongly agree) or a brain disorder (32.6% agree or strongly agree). There were high proportions of "don't know" responses for each item, suggesting that many were unfamiliar with the role of the brain in smoking, or did not feel confident enough to make a judgment. As a neutral option was not included in the scale, it is also possible that those who had a neutral position selected the "don't know" option.
Endorsement of Brain-Based Explanations of Smoking
Who Endorses Brain-Based Explanations of Smoking?
After excluding the participants who selected "don't know" for either of the key brain-related items, agreement with the statement that "smoking changes brain chemistry" was not significantly associated with gender, level of self-efficacy, or level of nicotine dependence, but it was strongly associated with age (see Table 2 ). There was a statistically significant difference in age (p < .001) between those who agreed that smoking changed the chemistry of the brain (M = 39.6, SD = 14.6) and those who disagreed (M = 44.1, SD = 17.6) Endorsement of the brain chemistry item was also associated with education. Those who had a Bachelor degree were more likely than those without a degree to agree that smoking changed brain chemistry (p = .02) Those who agreed that smoking changed brain chemistry were more likely than those who disagreed to intend to use medication on their next quit attempt (p < .001). There was no statistically significant association between agreement that smoking changed brain chemistry, or level of self-efficacy. Those who expressed a desire to quit smoking were more likely than those who had no desire to quit to agree that smoking changed brain chemistry (p < .001).
The findings were similar for endorsement of the statement that "smoking is a brain disease." Level of nicotine dependence was not related to endorsement while age was strongly related. Participants who agreed that smoking was a brain disease were younger (M = 38.2 years, SD = 16.6) than those who disagreed (M = 43.7 years, SD = 14.3) (p < .001). Females were significantly more likely to disagree that smoking was a brain disease than males (56.9% vs. 49.2%). Again, those with a university degree were more likely to agree that smoking was a brain disease (55.3%) than those without a degree (42.9%). Those who agreed that smoking was a brain disease had higher self-efficacy (p < .001), were more likely to express an intention to use medication (p < .001), and were more likely to report a desire to quit (p < .001). Table 3 shows that intention to use cessation medication was not related to age (OR 0.99, 95% CI = 0.98 to 1.00) or gender (OR 1.18, 95% CI = 0.87 to 1.60), once other socio-demographic factors were controlled for. Education was significantly related to intention to use cessation medications: those who had a university degree were more likely than those with no high school education to intend to use medications (OR 1.55, 95% CI = 1.12 to 2.20). Those with higher Figure 1 . Endorsement of brain-based explanations of smoking levels of nicotine dependence were more likely (OR 1.13, 95% CI = 1.02 to 1.25) to intend to use medications than those with lower levels of nicotine dependence. There were no statistically significant differences in intention to use medication between those with low and higher levels of self-efficacy, or between those with high or low desire to quit. Participants who agreed that smoking changed the chemistry of the brain were more likely to report an intention to use medication (OR 1.51, 95% CI = 1.03 to 2.21) as were those who Chi-square tests of independence used to test for statistical significance for categorical variables. T-test used for continuous variables. Agree = agree plus strongly agree, disagree = disagree plus strongly disagree. Medication = prescription medication or NRT. Agreement that smoking changes the chemistry of the brain = agree and strongly agree. Disagree that smoking changes the chemistry of the brain = disagree and strongly disagree. Agreement that smoking is a brain disease = agree and strongly agree. Disagree that smoking is a brain disease = disagree and strongly disagree.
Is Intention to use Medication Associated With Beliefs About the Neurobiological Basis of Smoking?
agreed that smoking was a brain disease (OR 1.54, 95% CI = 1.11 to 2.13). These effect sizes were statistically significant but only of moderate size. The biggest predictor of intention to use medications was past use: those who had used cessation medications in the past were more than twice as likely to intend to do so in the future (OR 2.68, 95% CI = 1.94 to 3.70).
Is Smoking Cessation Self-Efficacy Associated With Beliefs About the Neurobiological Basis of Smoking?
The results of the binary logistic regression testing the relationship between self-efficacy and beliefs about the role of the brain in smoking are shown in Table 4 . Gender, education, and past use of medication did not make a statistically significant contribution to the model. Those who were younger were less likely to report low self-efficacy (OR 0.98, 95% CI = 0.98 to 0.99), although this effect was small. Those who desired to quit had greater odds of reporting higher self-efficacy (OR 2.70, 95% CI = 1.57 to 4.64).
As expected, participants with high dependence had significantly lower levels of self-efficacy than those with low dependence (OR = 0.79, 95% CI = 0.72 to 0.87). There was no difference in self-efficacy between those who agreed and those who disagreed that smoking changed the chemistry of the brain (OR 0.80, 95% CI = 0.55 to 1.16). For the brain disease item, there was a statistically significant difference between those who agreed and disagreed: those who agreed that smoking was a brain disease were more likely to have high self-efficacy than those who disagreed (OR 1.70, 95% CI = 1.26 to 2.30).
Discussion
One aim of this study was to investigate the proportion of Australian smokers who endorse brain-based explanations of smoking. Such research has not been conducted in Australia previously, but it can indicate the extent to which smoking has been medicalized and whether smokers have adopted neuroscientific explanations of addiction. The results demonstrate that around one third of our sample of Australian smokers agreed that smoking was a brain disease, and a similar proportion did not know whether this was true. A higher proportion of participants agreed that smoking changes the chemistry of the brain, but a substantial proportion of participants were uncertain. This is consistent with recently published qualitative work, where most of the participants acknowledged that smoking influenced their brain, while disagreeing that it was a brain disease. 42 They believed the brain disease terminology was inaccurate and likely to lead to an increase in smoking related stigma.
We also found that those who were less educated were more likely to select the "don't know" responses for brain related items. This is consistent with other research on health and public understandings of science. 43, 44 It is unclear whether this is because the less educated have less knowledge of the topic of smoking and the brain, or they are less likely to express opinions on unfamiliar topics. The complexities of the "don't know" response have been outlined by social science researchers. 45, 46 A "don't know" response does not always signify ignorance, but can reflect "the absence of representation, to a sense that the question is irrelevant to the respondent and/or it may relate to the defensive needs of the individual." 45 Other items in the survey did not have such high proportions of participants selecting the "don't know" response. For example, on the items asking about intention to use various quitting options, rates of "don't know" responses were mostly between 10-14%, suggesting that the high levels of "don't know" options for the brain-related questions was not due to a general disengagement with the survey.
Another aim was to examine whether socio-demographic variables predicted endorsement of brain-based understandings of smoking. Endorsements of brain-based beliefs about smoking were N = 930. Self-efficacy: low = 0, moderate and high = 1. Sex: Female = 0, Male = 1. Desire to quit: 0=No desire, 1= some desire, Prior use of medication = ever used NRT or prescription medications for smoking cessation. Agreement that smoking changes the chemistry of the brain = agree and strongly agree. Disagree that smoking changes the chemistry of the brain = disagree and strongly disagree. Agreement that smoking is a brain disease = agree and strongly agree. Disagree that smoking is a brain disease = disagree and strongly disagree.
not uniform across social groups. Those who endorsed the stronger form of the "brain disease" explanation of smoking were more likely to be male, younger, have greater self-efficacy, more years of education, a desire to quit smoking, and intend to use medication on their next quit attempt. Those who agreed with the less controversial language that smoking changes the chemistry of the brain were also younger, more highly educated, and were more likely to intend to use medication than those with disagreed. These findings are discordant with predictions that the biomedical models of addiction will reduce self-efficacy in addicted individuals 23 but supports predictions that it could be related to the use of medications for cessation. As these are cross-sectional data, it is not possible to determine the direction of the relationship.
A third aim was to assess whether endorsement of brain-based explanations of smoking were associated with intention to use medication. While there was a positive relationship between intention to use cessation medication and endorsement of brain-based explanations of smoking, the strength of the association was modest. Based on these results, promoting brain-based explanations of smoking is unlikely to substantially increase the use of cessation medications. But it is unlikely to discourage uptake of cessation aids. A greater effect was seen for past use of medication, with those who had used medication in the past around three times more likely to do so in the future. This is consistent with research that those who have used cessation pharmacotherapies often report finding them helpful, 47 and that smokers who had used NRT or bupropion in the past were more likely to perceive them as helpful than those who had not tried them. 48 The last aim was to investigate whether acceptance of smoking as a brain disease was associated with self-efficacy. We found that agreement that smoking was a brain disease was associated with higher self-efficacy. This conflicts with predictions that promotion of biomedical understandings of addiction will increase fatalism about smoking. 23 While more research is required to confirm the findings, this suggests that neuroscience explanations of addiction, at least in relation to smoking, are not associated with a "fixed" mindset of behavior that results in reduced self-efficacy. 25 In fact, the qualitative evidence on this topic shows that addicted individuals often emphasize autonomy, choice and responsibility, which more closely represents a "growth" mindset. 31, 42 The size of many of these statistically significant associations were small, reflecting the large sample size used in this study. Statistical significance does not necessarily mean that the predictor variable will have practical significance or that changing the variable will have a substantial population level impact on smoking. Our findings suggest that endorsement of brain-based explanations of smoking have a relationship with treatment preferences and self-efficacy, but that the effect sizes are relatively small. However, the belief that smoking changes brain chemistry or is a brain disease in some cases had a larger effect than age, gender and level of nicotine dependence. Overall, the promotion of neurobiological models of smoking appear unlikely to negatively impact quitting at the population level.
A number of limitations of our study must be acknowledged. Firstly, participants were not recruited via random sampling. Participants were members of an online market research panel so may differ from smokers who were not members of this panel. While resourcing requirements ruled out the possibility of other sampling methods, such as random digit dialing, the changing nature of survey recruitment means that online panels are increasingly being used as a cost-effective and valid means of collecting survey data. 49 In addition, the validity of older methods of random sampling is being undermined by the increasing use of mobile phones and reductions in survey response rates. 50, 51 Also, our sample closely matched the Australian population of smokers in relation to age, gender, and being born overseas.
Future studies could employ educational materials to inform participants about the neurobiology of smoking and assess its impact on cessation attempts and self-efficacy, or focus groups to allow greater discussion and analysis of the complexity of neuroscientific research. Moreover, only self-reported attitudes have been investigated thus far, and it is unknown whether intentions and attitudes will impact on behavior. Behavioral choice experiments examining the impact of neurobiological explanations on participants' actual behavior (e.g., smoking, treatment choices, and quit attempts) are recommended.
On these results, it is possible that emphasizing the role of the brain could increase intention to use cessation pharmacotherapies but any such effect is likely to be small. Many factors influence a smoker's preference for cessation methods and their sense of selfefficacy, and the complexity of smokers' conceptions of addiction, the brain, and agency have been demonstrated in qualitative studies. 31, 52, 53 Overall, our results suggest that a neurobiological view of smoking does not dominate public understandings of nicotine addiction among smokers in Australia. When smokers do endorse brain-based explanations of smoking, this does not appear to reduce cessation self-efficacy, as has been suggested by some critics of medicalization.
Supplementary material
Supplementary data are available at Nicotine and Tobacco Research online. 
Funding
Declaration of Interests
None declared.
